Clinical trial
Predicting Inflammatory Skin Disease Response to IL-23 Blockade
Name
19-29813
Description
This study examines the effect of IL-23 blockade with Tildrakizumab on the immune cells of psoriatic skin lesions.
Trial arms
Trial start
2020-09-16
Estimated PCD
2023-01-15
Trial end
2023-01-15
Status
Completed
Phase
Early phase I
Treatment
Tildrakizumab
IL-23 inhibitor
Arms:
Tildrakizumab treatment
Size
7
Primary endpoint
Psoriasis Area and Severity Index (PASI) Score
baseline and 3 months
Eligibility criteria
Inclusion Criteria:
* Male or female ≥18 years of age at clinic visit.
* Documentation of moderate-severe psoriasis or atypical psoriasis.
* Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.
Exclusion Criteria:
* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data
* Tuberculosis, active serious infection, active systemic malignancy,
* Received a systemic medication for psoriasis within 3 months of study screening
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'BASIC_SCIENCE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 7, 'type': 'ACTUAL'}}
Updated at
2024-04-30
1 organization
1 product
1 indication
Organization
University of California, San FranciscoProduct
TildrakizumabIndication
Psoriasis Vulgaris